Intellia Therapeutics, Inc. (NTLA) analyst actions
Rating and price-target actions on NTLA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NTLA overview →
3 measured NTLA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema | Press release | -2.39% | -8.36% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out | Press release | +0.60% | -2.06% | |
| Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) | Press release | +0.50% | -0.67% |
Keep exploring
More NTLA: earnings → · SEC filings → · NTLA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Sage Therapeutics, Inc. (SAGE) | 951 | -0.14% | 41% |
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Biohaven Ltd. Common Shares (BHVN) | 944 | -0.27% | 45% |
| GW PHARMACEUTICALS PLC AMERICA (GWPH) | 942 | -0.06% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.